Vinay Prasad, director of the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), ...
Florida-based cell therapy company Gamida Cell has won US approval for Omisirge (omidubicel-onlv), the first hematopoietic ...
The European Commission has approved Roche’s Gazyva/Gazyvaro (obinutuzumab) in combination with mycophenolate mofetil (MMF) ...
Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and ...
GSK (LSE: GSK) has chosen to unwind its synthetic lethality alliance with US biotech Ideaya Biosciences (Nasdaq: IDYA), ...
Roche (ROG: SIX) has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ...
China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy ...
Italian pharma major Recordati’s rare diseases subsidiary announced the presentation of new data detailing advances in the ...
The US Association for Accessible Medicines (AAM) the leading trade association for generic and biosimilar manufacturers, ...
Kallyope is preparing to move its oral migraine candidate elismetrep toward registrational development after the TRPM8 ...
The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven ...
Ascletis Pharma (HKEX: 1672) has reported positive topline results from a 13-week Phase II study of ASC30, its once-daily oral GLP-1 agonist for obesity. All three doses met the primary endpoint with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback